1. X
  2. Journal of Clinical Oncology
Log inSign up
Journal of Clinical Oncology
12.7K posts
user avatar
Journal of Clinical Oncology
@JCO_ASCO
@ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
ascopubs.org/jco
Joined March 2014
1,134
Following
56.3K
Followers
RepliesRepliesMediaMedia
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

  • Pinned
    user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Dec 13, 2023
    Celebrating 40 years of pioneering oncology research with @ASCO's Journal of Clinical Oncology! We're thrilled to share this milestone in our history. Look forward to the reveal of our most-cited publication on 12/15. Discover the top-cited articles: [ascopubs.org/jco/40th-anniv…]
    00:00
    29K
  • user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Jul 24
    Reply to: “Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer” and “Uncontrolled Prediabetes Confounding in the Association Between Alcohol Consumption and Young-Onset Pancreatic Cancer.” Read the full article.
    ascopubs.org
    Reply to: “Beyond Average Grams: Aldehyde Dehydrogenase 2*2  and Alcohol-Induced Young-Onset...
    1.9K
  • user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Jul 24
    Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Read the full article.
    ascopubs.org
    Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor...
    Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective response rates (ORRs) of 21%-24% in recurrent/metastatic (R/M) head/neck squamous...
    2K
  • user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Jul 24
    Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Co-authored by @GIcancerDoc. Read the full article.
    ascopubs.org
    Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor...
    PURPOSECholangiocarcinoma is a rare cancer associated with poor prognosis. Pemigatinib was the first FGFR1-3 inhibitor approved for second-line therapy and beyond, on the basis of the phase II...
    12K
  • user avatar
    Journal of Clinical Oncology
    @JCO_ASCO
    Jul 24
    All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). Co-authored by @GhayasIssa. Read the full article.
    ascopubs.org
    All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
    PURPOSERevumenib is an oral inhibitor of menin-KMT2A, a key dependency in acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar), NPM1 mutation (NPM1mt), or NUP98 rearrangement (NUP98r)....
    2.1K